Asset
UMBRALISIB
TG Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01767766 | phase1 | completed | 2013-01-07 | 2018-02-01 | TG Therapeutics, Inc. | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies |
| NCT03207256 | phase2 | terminated | 2017-08-09 | 2022-05-25 | TG Therapeutics, Inc. | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials |
| NCT02164006 | phase1 | completed | 2014-06-11 | 2016-05-01 | TG Therapeutics, Inc. | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients |
| NCT02574663 | phase1 | completed | 2015-09-11 | 2018-08-01 | TG Therapeutics, Inc. | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors |
| NCT02100852 | phase1 | completed | 2014-03-12 | 2017-11-01 | TG Therapeutics, Inc. | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) |
FDA applications (0)
This company has no applications containing this asset.